IDH2 and acute myeloid leukemia: Two orally bioavailable IDH inhibitors, enasidenib (IDH2 inhibitor) and ivosidenib (IDH1 inhibitor) are now FDA-approved [19,20]: the former for the treatment of IDH2-mutated relapsed-refractory AML, and the latter for both IDH1-mutated relapsed-refractory and newly diagnosed AML unfit for intensive chemotherapy.